On March 4, 2026 Denovicon Therapeutics, Inc. reported the discovery of DNT-1569, a small molecule inhibitor of poly(ADP-ribose) polymerase 7 (PARP7) designed as a potential oral immunomodulatory therapy for solid tumors. To the best of our knowledge, no small molecule immuno-oncology drug has reached the market — the entire immunotherapy revolution to date relies on biologics. DNT-1569 is designed to change that. The compound demonstrates potent PARP7 inhibition with approximately 2,000-fold selectivity over PARP1 and 2,500-fold selectivity over PARP2 — a selectivity profile that distinguishes it from all known PARP7 inhibitors, including the clinical compound RBN-2397 (atamparib).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Why PARP7 — and Why Selectivity Matters
After nearly 25 years in drug discovery — including 17 years at Johnson & Johnson, where I co-led seven clinical candidates — one pattern stands out: good mechanisms fail when the molecules carrying them aren’t clean enough to dose properly.

PARP7 is a compelling immuno-oncology target. Inhibiting PARP7 restores type I interferon signaling in tumor cells, activating the innate immune system and potentially converting immunologically "cold" tumors — the ones that don’t respond to checkpoint inhibitors like Keytruda — into "hot" tumors that the immune system can recognize and attack. PARP7 is dysregulated across multiple solid tumor types, including lung, breast, ovarian, head and neck, pancreatic, and colorectal cancers.

The clinical precedent exists. Ribon Therapeutics’ RBN-2397 entered Phase 1 trials and demonstrated preliminary antitumor activity, establishing proof of concept that PARP7 inhibition produces clinical benefit. But RBN-2397 is not a selective PARP7 inhibitor — it potently inhibits PARP1 and PARP2 as well, which creates the same hematological toxicities seen with traditional PARP inhibitors. This likely resulted in tox-limited dosing and, consequently, the achievable efficacy.

The mechanism is validated. The selectivity problem was not.

DNT-1569: Solving the Selectivity Problem
DNT-1569 was designed to be the PARP7 inhibitor that RBN-2397 was not — one that inhibits the intended target without carrying off-target PARP1/2 liabilities.

Biochemical Profile:

DNT-1569 (Denovicon) RBN-2397 (Ribon)
PARP7 4 nM 3 nM
PARP1 8,000 nM 37 nM
PARP2 10,000 nM 17 nM
PARP1 Selectivity ~2,000× ~12×
PARP2 Selectivity ~2,500× ~6×
Scaffold Novelty Tanimoto = 0.14 vs. RBN-2397 —
Virtual Design Time < 2 days Years (traditional)
DNT-1569 matches RBN-2397’s PARP7 potency while pushing PARP1 and PARP2 activity into the micromolar range. This selectivity profile is designed to enable full therapeutic dosing of PARP7 without the PARP1/2-driven toxicities that likely constrained RBN-2397’s clinical performance.

Importantly, DNT-1569 sits on a novel chemical scaffold — a Tanimoto similarity of 0.14 relative to RBN-2397 confirms that this is not an analogue or derivative of existing PARP7 chemistry. The compound emerged from an entirely different design process, not from iterating on a known scaffold.

How We Got Here
DNT-1569 was designed using Denovicon’s computational drug discovery platform, which uses physics-based machine learning to design molecules with druglike properties built in from the start — not optimized after the fact.

Rather than starting with target affinity and then spending years trying to engineer in druglike properties — the traditional break-fix cycle that accounts for the majority of preclinical program failures — our approach optimizes across ADMET, pharmacokinetic, toxicity, and affinity properties from the outset. Every design decision maps to real chemical features that medicinal chemists can interrogate — no black boxes.

The entire virtual design phase for DNT-1569 was completed in under two days. The program from inception to the selectivity data reported here took under one year.

Since the DNT-1569 program, Denovicon’s platform has evolved into a quantum physics-driven generative AI architecture that extends these capabilities to trillion-molecule chemical spaces, enabling simultaneous multi-objective optimization in a single computational step. The core principle remains the same: build druglikeness in by design. The scale and speed at which we can now do it has fundamentally changed.

Clinical Implications
The immuno-oncology landscape is dominated by biologics — checkpoint inhibitors, CAR-T therapies, bispecific antibodies — all of which require infusion, cold chain logistics, specialized administration, and carry substantial cost. To the best of our knowledge, there is no marketed small molecule immuno-oncology drug. DNT-1569 is designed to address that gap: an oral small molecule that modulates the immune system’s ability to recognize and attack tumors.

A truly selective small molecule PARP7 inhibitor opens two therapeutic paths.

Monotherapy: If PARP7 inhibition alone is sufficient to drive antitumor immunity in selected patient populations — as early evidence in squamous cell lung cancer and head and neck cancers suggests — a selective oral PARP7 inhibitor could offer meaningful clinical benefit without the toxicity burden of pan-PARP inhibition. As a small molecule, it reaches compartments that antibodies cannot — including the central nervous system — and can be manufactured and distributed at a fraction of the cost of biologics.

Combination therapy: The greater opportunity may lie in combining a selective PARP7 inhibitor with existing immune checkpoint inhibitors. Approximately 70% of cancer patients do not respond to checkpoint inhibitors alone, largely because their tumors are immunologically cold. A selective PARP7 inhibitor that activates the type I interferon pathway — turning cold tumors hot — could serve as an oral immunomodulatory backbone for checkpoint inhibitor combinations. Critically, this combination is viable only if the PARP7 inhibitor does not add significant toxicity to the regimen. DNT-1569’s selectivity profile is designed to make that combination feasible.

An oral, well-tolerated small molecule immunomodulator would represent a new therapeutic modality — one with implications not just for efficacy, but for global patient access.

What Comes Next
Immune biomarker assays for DNT-1569 are underway. These data will provide the first readout on whether the selectivity advantage observed in biochemical assays translates to the expected immunomodulatory activity in cellular systems. Denovicon is actively engaging pharmaceutical partners for proof-of-concept collaborations around the PARP7 program and the broader quantum physics-driven generative AI platform.

(Press release, Denovicon Therapeutics, MAR 4, 2026, View Source [SID1234663214])